牛牛AI助理已提取核心訊息
On February 22, 2024, Bristol-Myers Squibb successfully completed a significant public offering of various notes totaling $11.25 billion. The offering included Floating Rate Notes due 2026 and Fixed Rate Notes with maturity dates ranging from 2026 to 2064, with interest rates between 4.900% and 5.650%. The notes were issued under an Indenture agreement with The Bank of New York Mellon as trustee. Bristol-Myers Squibb intends to allocate a portion of the net proceeds towards funding its proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., as well as related fees and expenses. Remaining proceeds are earmarked for general corporate purposes. The offering is not dependent on the completion of the acquisitions; however, if the acquisition of Karuna does not occur by a specified date, the company will be required to redeem the notes at a price of 101% of their aggregate principal amount plus accrued interest. The notes were sold under an underwriting agreement dated February 14, 2024, with the terms detailed in a Prospectus Supplement filed with the SEC.
On February 22, 2024, Bristol-Myers Squibb successfully completed a significant public offering of various notes totaling $11.25 billion. The offering included Floating Rate Notes due 2026 and Fixed Rate Notes with maturity dates ranging from 2026 to 2064, with interest rates between 4.900% and 5.650%. The notes were issued under an Indenture agreement with The Bank of New York Mellon as trustee. Bristol-Myers Squibb intends to allocate a portion of the net proceeds towards funding its proposed acquisitions of Karuna Therapeutics, Inc. and RayzeBio, Inc., as well as related fees and expenses. Remaining proceeds are earmarked for general corporate purposes. The offering is not dependent on the completion of the acquisitions; however, if the acquisition of Karuna does not occur by a specified date, the company will be required to redeem the notes at a price of 101% of their aggregate principal amount plus accrued interest. The notes were sold under an underwriting agreement dated February 14, 2024, with the terms detailed in a Prospectus Supplement filed with the SEC.
2024年2月22日，百時美施貴寶成功完成了總額爲112.5億美元的各種票據的重大公開募股。此次發行包括2026年到期的浮動利率票據和到期日介於2026年至2064年之間的固定利率票據，利率在4.900％至5.650％之間。這些票據是根據契約協議發行的，紐約梅隆銀行是受託人。百時美施貴寶打算將部分淨收益用於爲其對Karuna Therapeutics, Inc.和RayzeBio, Inc. 的擬議收購以及相關費用和支出提供資金。剩餘收益專用於一般公司用途。此次發行不取決於收購的完成；但是，如果未在指定日期之前收購Karuna，則公司將被要求以本金總額的101％加上應計利息的價格贖回票據。這些票據是根據2024年2月14日的承保協議出售的，其條款詳見向美國證券交易委員會提交的招股說明書補充文件。
2024年2月22日，百時美施貴寶成功完成了總額爲112.5億美元的各種票據的重大公開募股。此次發行包括2026年到期的浮動利率票據和到期日介於2026年至2064年之間的固定利率票據，利率在4.900％至5.650％之間。這些票據是根據契約協議發行的，紐約梅隆銀行是受託人。百時美施貴寶打算將部分淨收益用於爲其對Karuna Therapeutics, Inc.和RayzeBio, Inc. 的擬議收購以及相關費用和支出提供資金。剩餘收益專用於一般公司用途。此次發行不取決於收購的完成；但是，如果未在指定日期之前收購Karuna，則公司將被要求以本金總額的101％加上應計利息的價格贖回票據。這些票據是根據2024年2月14日的承保協議出售的，其條款詳見向美國證券交易委員會提交的招股說明書補充文件。
有用
沒用
